Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?

Bone Marrow Transplantation volume 48, pages 1013–1021 (2013)Cite this article

Subjects

Abstract

The role of autologous hematopoietic cell transplantation (auto-HCT) in the management of indolent non-Hodgkin lymphomas (NHL) is shrouded in controversy. The outcomes of conventional therapies for many indolent lymphoma subtypes have dramatically improved over the last several years with the use of monoclonal antibodies, maintenance therapy programs and with the incorporation of radio-immunoconjugates. These significant advances in the armamentarium of lymphoma therapeutics warrant reappraisal of the current role of auto-HCT in the treatment algorithm of indolent NHL. Prospective randomized studies comparing contemporary chemoimmunotherapies against auto-HCT are lacking, leading to significant debate about the role and timing of auto-HCT for indolent NHL in the modern era. Although autografting for follicular lymphoma (FL) in first remission has been largely abandoned, it remains a useful modality for relapsed disease, especially for the subgroup of patients who are not candidates for allogeneic transplantation with a curative intent. Auto-HCT can provide durable disease control in chemosensitive transformed FL and mantle cell lymphoma (MCL) in first remission, with relatively low toxicity, and remains appropriate in chemoimmunotherapy era. Contemporary data are also reviewed to clarify the often underutilized role of autografting in relapsed MCL and other less frequent indolent NHL histologies. The biological basis of the increased risks of second malignancies with auto-HCT are reviewed to identify strategies designed to mitigate this risk by, for example, avoiding exposure to genotoxic agents, planning early stem cell collection/cryopreservation and minimizing the use of TBI with transplant conditioning, and so on. Genetic testing able to identify patients at high risk of therapy-related complications and novel post-transplant immune therapies with the potential of transforming autografting in indolent NHL from a remission-extending therapy to a curative modality are discussed to examine the possibly expanding role of auto-HCT for lymphoid malignancies in the coming years.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  2. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 1987; 316: 1493–1498.

    Article  CAS  PubMed  Google Scholar 

  3. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184–4190.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359: 2065–2071.

    Article  CAS  PubMed  Google Scholar 

  5. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42–51.

    Article  CAS  PubMed  Google Scholar 

  6. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732.

    Article  CAS  PubMed  Google Scholar 

  7. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156–5164.

    Article  CAS  PubMed  Google Scholar 

  8. Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: 4926–4933.

    Article  PubMed  Google Scholar 

  9. Ayala E, Tomblyn M . Hematopoietic cell transplantation for lymphomas. Cancer Control 2011; 18: 246–257.

    Article  PubMed  Google Scholar 

  10. Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13: 1057–1065.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667–2674.

    Article  CAS  PubMed  Google Scholar 

  12. Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 2006; 108: 2540–2544.

    Article  CAS  PubMed  Google Scholar 

  13. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004–4013.

    Article  CAS  PubMed  Google Scholar 

  14. Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009; 113: 995–1001.

    Article  CAS  PubMed  Google Scholar 

  15. Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824–4831.

    Article  CAS  PubMed  Google Scholar 

  16. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579–4586.

    Article  CAS  PubMed  Google Scholar 

  17. Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N . High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Cochrane Database Syst Rev 2012; 1: CD007678.

    PubMed  Google Scholar 

  18. Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M . Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104: 18–28.

    Article  PubMed  Google Scholar 

  19. Kahl B, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 2011; 118 LBA-6.

  20. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO . High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol 1997; 15: 445–450.

    Article  CAS  PubMed  Google Scholar 

  21. Cao TM, Horning S, Negrin RS, Hu WW, Johnston LJ, Taylor TL et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7: 294–301.

    Article  CAS  PubMed  Google Scholar 

  22. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.

    Article  CAS  PubMed  Google Scholar 

  23. Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008; 26: 3614–3620.

    Article  CAS  PubMed  Google Scholar 

  24. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25: 2554–2559.

    Article  PubMed  Google Scholar 

  25. Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007; 21: 2324–2331.

    Article  CAS  PubMed  Google Scholar 

  26. van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529.

    Article  CAS  PubMed  Google Scholar 

  27. Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol 2008; 26: 3166–3175.

    Article  CAS  PubMed  Google Scholar 

  28. Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007; 13: 956–964.

    Article  PubMed  Google Scholar 

  29. Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102: 2351–2357.

    Article  CAS  PubMed  Google Scholar 

  30. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.

    CAS  PubMed  Google Scholar 

  31. Tarella C, Corradini P, Astolfi M, Bondesan P, Caracciolo D, Cherasco C et al. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Leukemia 1999; 13: 1456–1462.

    Article  CAS  PubMed  Google Scholar 

  32. Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 2008; 19: 1331–1335.

    Article  CAS  PubMed  Google Scholar 

  33. Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009; 43: 701–708.

    Article  CAS  PubMed  Google Scholar 

  34. Crippa F, Holmberg L, Carter RA, Hooper H, Marr KA, Bensinger W et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 281–289.

    Article  PubMed  Google Scholar 

  35. Pettengell R, Schmitz N, Gisselbrecht C, Caballero D, Colombat P, Conde E et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. J Clin Oncol 2010; 28: 8005.

    Article  Google Scholar 

  36. Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant 2011; 17: 1051–1057.

    Article  PubMed  Google Scholar 

  37. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26: 5165–5169.

    Article  PubMed  Google Scholar 

  38. Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999; 5: 262–268.

    Article  CAS  PubMed  Google Scholar 

  39. Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001; 19: 727–735.

    Article  CAS  PubMed  Google Scholar 

  40. Chen CI, Crump M, Tsang R, Stewart AK, Keating A . Autotransplants for histologically transformed follicular non-Hodgkin’s lymphoma. Br J Haematol 2001; 113: 202–208.

    Article  CAS  PubMed  Google Scholar 

  41. Hamadani M, Benson DM, Lin TS, Porcu P, Blum KA, Devine SM . High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol 2008; 81: 425–431.

    Article  PubMed  Google Scholar 

  42. Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenholder M et al. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol 2011; 152: 600–610.

    Article  CAS  PubMed  Google Scholar 

  43. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008; 113: 791–798.

    Article  PubMed  Google Scholar 

  44. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200–208.

    CAS  PubMed  Google Scholar 

  45. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677–2684.

    Article  CAS  PubMed  Google Scholar 

  46. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101–6108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520–531.

    Article  CAS  PubMed  Google Scholar 

  49. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511–518.

    Article  PubMed  Google Scholar 

  50. Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257–262.

    Article  CAS  PubMed  Google Scholar 

  51. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, Lopez-Guillermo A, Gisselbrecht C et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800.

    Article  PubMed  Google Scholar 

  52. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144–4152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a phase II study from the GELA. Blood e-pub ahead of print 20 June 2012.

  54. Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355–362.

    Article  CAS  PubMed  Google Scholar 

  55. Andersen NS, Pedersen L, Elonen E, Johnson A, Kolstad A, Franssila K et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003; 71: 73–80.

    Article  PubMed  Google Scholar 

  56. Epner E, Unger J, Miller T, Rimzsa L, Spier C, Leblanc M et al. A multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 2007; 110: 387.

    Google Scholar 

  57. Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 2011; 29: 3023–3029.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Geisler CH, Kolstad A, Laurell A, Raty R, Jerkeman M, Eriksson M et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115: 1530–1533.

    Article  CAS  PubMed  Google Scholar 

  59. Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156: 346–353.

    Article  CAS  PubMed  Google Scholar 

  60. Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 690–697.

    Article  CAS  PubMed  Google Scholar 

  61. Hill BT, Rybicki L, Smith S, Dean R, Kalaycio M, Pohlman B et al. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. Leuk Lymphoma 2011; 52: 986–993.

    Article  CAS  PubMed  Google Scholar 

  62. Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2012; 23: 166–171.

    Article  CAS  PubMed  Google Scholar 

  63. Hamadani M, Craig M, Awan FT, Devine SM . How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45: 1259–1268.

    Article  CAS  PubMed  Google Scholar 

  64. Ketterer N, Salles G, Espinouse D, Dumontet C, Neidhardt-Berard EM, Moullet I et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997; 8: 701–704.

    Article  CAS  PubMed  Google Scholar 

  65. Milpied N, Gaillard F, Moreau P, Mahe B, Souchet J, Rapp MJ et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998; 22: 645–650.

    Article  CAS  PubMed  Google Scholar 

  66. Vose JM, Bierman PJ, Weisenburger DD, Lynch JC, Bociek Y, Chan WC et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000; 6: 640–645.

    Article  CAS  PubMed  Google Scholar 

  67. Till BG, Gooley TA, Crawford N, Gopal AK, Maloney DG, Petersdorf SH et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008; 49: 1062–1073.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Fenske TS, Carreras J, Zhang M, Laport G, Montoto S, Maloney D et al. Outcome of patients with mantle cell lymphoma undergoing autologous versus reduced-intensity allogeneic transplantation. Ann Oncol 2011; 22: iv87.

    Google Scholar 

  69. Treon SP . How I treat Waldenstrom macroglobulinemia. Blood 2009; 114: 2375–2385.

    Article  CAS  PubMed  Google Scholar 

  70. Gertz MA . Waldenstrom macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 503–510.

    Article  CAS  PubMed  Google Scholar 

  71. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol 2009; 27: 120–126.

    Article  PubMed  Google Scholar 

  72. Anagnostopoulos A, Giralt S . Stem cell transplantation (SCT) for Waldenstrom’s macroglobulinemia (WM). Bone Marrow Transplant 2002; 29: 943–947.

    Article  CAS  PubMed  Google Scholar 

  73. Anagnostopoulos A, Hari PN, Perez WS, Ballen K, Bashey A, Bredeson CN et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom’s macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845–854.

    Article  PubMed  Google Scholar 

  74. Gilleece MH, Pearce R, Linch DC, Wilson M, Towlson K, Mackinnon S et al. The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology 2008; 13: 119–127.

    Article  PubMed  Google Scholar 

  75. Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N et al. Transplantation in Waldenstrom’s macroglobulinemia--the French experience. Semin Oncol 2003; 30: 291–296.

    Article  CAS  PubMed  Google Scholar 

  76. Dhedin N, Tabrizi R, Bulabois P, Le Gouill S, Coiteux V, Dartigeas C et al. Hematopoietic stem cell transplantation (HSCT) in waldenstrom macroglobulinemia (WM), update of the French experience in 54 cases. Haematologica 2007; 92: 228.

    Google Scholar 

  77. Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 2227–2232.

    Article  CAS  PubMed  Google Scholar 

  78. Nichols GL, Skerrett DL . Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia. Stem Cells Dev 2005; 14: 3–5.

    Article  CAS  PubMed  Google Scholar 

  79. Gertz MA, Reeder CB, Kyle RA, Ansell SM . Stem cell transplant for Waldenstrom macroglobulinemia: an underutilized technique. Bone Marrow Transplant 2012; 47: 1147–1153.

    Article  CAS  PubMed  Google Scholar 

  80. Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL et al. Autologous bone marrow transplantation for marginal zone non-Hodgkin’s lymphoma. Leuk Lymphoma 2004; 45: 315–320.

    Article  PubMed  Google Scholar 

  81. Li L, Bierman P, Vose J, Loberiza F, Armitage JO, Bociek RG . High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2011; 11: 253–256.

    Article  CAS  PubMed  Google Scholar 

  82. Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M et al. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood 2011; 117: 1516–1521.

    Article  CAS  PubMed  Google Scholar 

  83. Sutton L, Chevret S, Tournilhac O, Divine M, Leblond V, Corront B et al. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood 2011; 117: 6109–6119.

    Article  CAS  PubMed  Google Scholar 

  84. Montserrat E, Gribben JG . Autografting CLL: the game is over!. Blood 2011; 117: 6057–6058.

    Article  CAS  PubMed  Google Scholar 

  85. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.

    Article  CAS  PubMed  Google Scholar 

  86. Hake CR, Graubert TA, Fenske TS . Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant 2007; 39: 59–70.

    Article  CAS  PubMed  Google Scholar 

  87. Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 2005; 23: 2208–2214.

    Article  CAS  PubMed  Google Scholar 

  88. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 1994; 12: 2535–2542.

    Article  CAS  PubMed  Google Scholar 

  89. Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003; 101: 2015–2023.

    Article  CAS  PubMed  Google Scholar 

  90. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Ann Oncol 2002; 13: 450–459.

    Article  CAS  PubMed  Google Scholar 

  91. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947–955.

    Article  CAS  PubMed  Google Scholar 

  92. Milligan DW, Ruiz De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT lymphoma and late effects working parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106: 1020–1026.

    Article  CAS  PubMed  Google Scholar 

  93. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T . High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004; 103: 2316–2324.

    Article  CAS  PubMed  Google Scholar 

  94. Christiansen DH, Andersen MK, Pedersen-Bjergaard J . Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19: 1405–1413.

    Article  CAS  PubMed  Google Scholar 

  95. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J . Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2005; 19: 2232–2240.

    Article  CAS  PubMed  Google Scholar 

  96. Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001; 98: 11592–11597.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Allan JM, Smith AG, Wheatley K, Hills RK, Travis LB, Hill DA et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004; 104: 3872–3877.

    Article  CAS  PubMed  Google Scholar 

  98. Bhatia R, Van Heijzen K, Palmer A, Komiya A, Slovak ML, Chang KL et al. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol 2005; 23: 6699–6711.

    Article  PubMed  Google Scholar 

  99. Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin’s lymphoma and Hodgkin’s disease: a clinical and molecular analysis. Bone Marrow Transplant 1999; 24: 473–481.

    Article  CAS  PubMed  Google Scholar 

  100. Weisdorf DJ, Verfaille CM, Miller WJ, Blazar BR, Perry E, Shu XO et al. Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: a prospective, comparative trial. Am J Hematol 1997; 54: 202–208.

    Article  CAS  PubMed  Google Scholar 

  101. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2009; 27: 1653–1659.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Vose JM, Carter S, Burns L, Ayala E, Press O, Moskowitz CH et al. Randomized phase III trial of 131iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): no difference in progression-free (PFS) or overall survival (OS). Blood 2011; 18: 661.

    Google Scholar 

  103. Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002; 29: 56–69.

    Article  CAS  PubMed  Google Scholar 

  104. Brody JD, Goldstein MJ, Czerwinski DK, Levy R . Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 2009; 113: 85–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Holman PR, Costello C, de Magalhaes-Silverman M, Corringham S, Castro J, Ball ED . Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2012; 18: 257–264.

    Article  PubMed  Google Scholar 

  106. Porter DL, Levine BL, Kalos M, Bagg A, June CH . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725–733.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

MH is supported by the Conquer Cancer Foundation of the ASCO Career Development Award, and the ASBMT and Millennium New Investigator Award.

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Myeloma and Lymphoma Service, Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA

    M Hamadani

Authors
  1. M Hamadani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Hamadani.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamadani, M. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?. Bone Marrow Transplant 48, 1013–1021 (2013). https://doi.org/10.1038/bmt.2012.182

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.182

Keywords

Search

Advanced search

Quick links